Delivery Order SPE2DB22D3004-SPE2DB25FNE17

Award Date 10/9/24
Potential Completion Date 10/10/24
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,489.88 contract is to provide NARCAN 4 MG NASAL SPRAY 2S, a medication used to reverse opioid overdose. This is a single award under the DLA's $999,999,999 Indefinite Delivery Contract (IDC) with AmerisourceBergen, which serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical products and...
This is a $1,102.28 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of NARCAN 4 MG NASAL SPRAY 2S. The contract has an ultimate completion date of July 18, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,620.35 contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to reverse opioid overdoses. The contract has an ultimate completion date of January 20, 2023. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of NARCAN 4 MG NASAL SPRAY. The contract has a firm fixed price of $1,050.48 and an ultimate completion date of July 9, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical division, which serves as the primary vehicle for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,463.04 contract is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for the treatment of opioid overdose. The award is not associated with a set-aside program and does not appear to be part of a larger indefinite delivery contract vehicle. However, the vendor does hold a...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,251.76, is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a medication used to reverse opioid overdose. The contract has a firm fixed price pricing type and an ultimate completion date of November 21, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,392.96 contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for the company to...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $3,581.28 firm fixed price contract is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a medication used to treat opioid overdose. This delivery order is issued under an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 held by Amerisourcebergen Drug Corp, which serves as...
This federal contract award, valued at $4,337.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for opioid overdose reversal. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication, with a ceiling value of $8,804.66. The contract has an ultimate completion date of April 27, 2023 and is a firm fixed-price delivery order. AmerisourceBergen holds a larger Indefinite Delivery...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB25FNE17
    Delivery Order

This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,400.64 fixed-price contract is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical to provide a comprehensive range of medical commodities for military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is scheduled for completion by October 10, 2024.

Generated 1/8/25, 9:13 AM